World Health OrganizationWHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship. World Health Organization 2013.
Prochaska JJ. Smoking and mental illness-breaking the link. N Engl J Med 2011; 365(3): 196-8.
Sadock BJ, Sadock VA. Kaplan and Sadock’s synopsis of psychiatry: Behavioral sciences/clinical psychiatry. Lippincott Williams & Wilkins 2014; pp. pp. 680-685.
Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25(2): 83-8.
Himelhoch S, Lehman A, Kreyenbuhl J, Daumit G, Brown C, Dixon L. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry 2004; 161(12): 2317-9.
Dickerson F, Origoni A, Schroeder J, et al. Mortality in schizophrenia and bipolar disorder: clinical and serological predictors. Schizophr Res 2016; 170: 177-83.
Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15: 469-94.
Tidey JW, Rohsenow DJ. Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls. Schizophr Res 2009; 115(2-3): 310-6.
Williams JM. Eliminating tobacco use in mental health facilities: patients’ rights, public health, and policy issues. JAMA 2008; 299: 571-3.
Ragg M, Gordon R, Ahmed T, Allan J. The impact of smoking cessation on schizophrenia and major depression. Australas Psychiatry 2013; 21: 238-45.
George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia2000 Am J Psychiatry 2000; 157(1): 835-42.
Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27(4): 380-6.
Grizzell JA, Echeverria V. New insights into the mechanisms of action of cotinine and its distinctive effects from nicotine. Neurochem Res 2015; 40(10): 2032-46.
Dickerson F, Stallings CR, Origoni AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv 2013; 64(1): 44-50.
Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362(24): 2295-303.
Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction--The implications for tobacco regulation. N Engl J Med 1994; 331(2): 123-5.
Balfour DJ. The psychobiology of nicotine dependence. Eur Respir Rev 2008; 17(110): 172-81.
Stahl SM. Stahl's essential psychopharmacology: Neuroscientific
basis and practical applications. Cambridge university press; 2013
Kelley AE. Memory and addiction: Shared neural circuitry and molecular mechanisms. Neuron 2004; 44(1): 161-79.
Kelly C, McCreadie R. Cigarette smoking and schizophrenia. Adv Psychiatr Treat 2013; 15(5): 322-7.
de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: An epidemiological survey in a state hospital. Am J Psychiatry 1995; 152(3): 453-5.
de Leon J, Tracy J, McCann E, McGrory A, Diaz FJ. Schizophrenia and tobacco smoking: A replication study in another US psychiatric hospital. Schizophr Res 2002; 56(1-2): 55-65.
Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. Annu Rev Med 2016; 67: 467-86.
de Leon J, Diaz FJ. Genetics of schizophrenia and smoking: An approach to studying their comorbidity based on epidemiological findings. Hum Genet 2012; 131(6): 877-901.
Hall SE, Prochaska JJ. Clinical issues and strategies associated with smoking cessation. Psychiatr Times 2015; 32(3): 57.
de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002; 56(1-2): 47-54.
Manzella F, Maloney SE, Taylor GT. Smoking in schizophrenic patients: A critique of the self-medication hypothesis. World J Psychiatry 2015; 5(1): 35.
Schwartz K, Iancu I, Stryjer R, et al. Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients. Eur Neuropsychopharmacol 2005; 15: 557-61.
Annamalai A, Singh N, O’Malley SS. Focus: Addiction: Smoking use and cessation among people with serious mental illness. Yale J Biol Med 2015 Sep; 88(3): 271.
Vokes NI, Bailey JM, Rhodes KV. “Should I give you my smoking lecture now or later?” Characterizing emergency physician smoking discussions and cessation counseling. Ann Emerg Med 2006; 48(4): 406-14.
Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004; 29(6): 1067-83.
Himelhoch S, Riddle J, Goldman HH. Barriers to implementing evidence-based smoking cessation practices in nine community mental health sites. Psychiatr Serv 2014; 65(1): 75-80.
Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143(8): 993-7.
Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005; 14(2): 106-23.
García-Portilla MP, Bobes J. Smoking cessation programs for persons with schizophrenia: An urgent unmet need. Rev Psiquiatr Salud Ment 2016; 9(4): 181.
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76(2): 135-57.
Paolini M, De Biasi M. Mechanistic insights into nicotine withdrawal. Biochem Pharmacol 2011; 82(8): 996-1007.
Tuesta LM, Fowler CD, Kenny PJ. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol 2011; 82(8): 984-95.
Dawe S, Gray JA, Russell MA, Gerda C. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl) 1995; 117(1): 110-5.
Zhang XY, Liang J, Xiu MH, et al. Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS One 2012; 7(2): e30937.
Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11(11): CD000146.
Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012; 40(3): 548-54.
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta‐analysis. Cochrane Database Syst Rev 2013; (5): CD009329.
Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23(2): 247-54.
Addington J, El-Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998; 155(7): 974-5.
Ezat WS, Selahuddeen AA, Aljunid SM, Zarihah Z. Patterns and predictors of smoking cessation among smokers attending smoking cessation clinics in Peninsular Malaysia. Jurnal Kesihatan Masyarakat 2008; 14(1): 17-23.
Hughes JR, Stead LF, Hartmann‐Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. The Cochrane Libr 2014.
Cinciripini PM, Robinson JD, Karam-Hage M, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 2013; 70(5): 522-33.
Rau KS, Birdsall E, Hanson JE, et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005; 49(6): 820-30.
Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry 2012; 95-102.
Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: Systematic review and meta-analysis. Br J Psychiatry 2010; 196(5): 346-53.
Turner JR, Castellano LM, Blendy JA. Parallel anxiolytic-like effects andupregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res 2011; 13(1): 41-6.
Smith RC, Amiaz R, Si TM, et al. Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: A double-blind randomized trial. PLoS One 2016; 11(1): e0143490.
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 47-55.
Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 56-63.
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
Mills EJ, Wu P, Lockhart I, et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012; 44(6): 588-97.
Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CAMJ 2008; 179(2): 135-44.
Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170(12): 1460-7.
Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164(8): 1269.
Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164(8): 1269-70.
Nino-Gomez J, Carlini S, Nemani K, et al.
Safety and efficacy of
varenicline in schizophrenia: Preliminary data from 12-week trial.
InAbstract presented at the 16th Annual Meeting of the Society for
Research on Nicotine and Tobacco
2010 Feb 24.;
Ismail Z, Syms J, Blumberger D, George TP. Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia. Schizophr Res 2010; 119: 268.
Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: A case series. J Clin Psychiatry 2008; 69(6): 1016.
Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009; 65(2): 144-9.
Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 2010; 4: 355.
Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of Varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110(1-3): 149-55.
Weiner E, Buchholtz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011; 129(1): 94.
Pachas GN, Cather C, Pratt SA, et al. Varenicline for smoking cessation in schizophrenia: Safety and effectiveness in a 12-week open-label trial. J Dual Diagn 2012; 8(2): 117-25.
Matthews AM, Wilson VB, Mitchell SH. The role of antipsychotics in smoking and smoking cessation. CNS Drugs 2011; 25(4): 299-315.
McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995; 119(1): 124-6.
Chatterton R, Sanderson L, Van Leent S, Plant K. Does clozapine affect smoking rates? Aust N Z J Psychiatry 1998; 32(6): 890-1.
George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56(8): 344-6.
McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37: 550-2.
Palazzolo DL. Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review. Front Public Health 2013; 1: 56.
Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health 2013; 10(2): 446-61.
Orr KK, Asal NJ. Efficacy of electronic cigarettes for smoking cessation. Ann Pharmacother 2014; 48(11): 1502-6.